Education
About Us
Working with TipRanks
Follow Us
Pasithea Therapeutics Corp. (KTTA)
:KTTA
KTTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $7.50
Previous CloseN/A
Volume25.24K
Average Volume (3M)124.55K
Market Cap
$5.20M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.69
Shares Outstanding7,443,577
10 Day Avg. Volume123,014
30 Day Avg. Volume124,550
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pasithea Therapeutics Corp News
KTTA FAQ
What was Pasithea Therapeutics Corp.’s price range in the past 12 months?
Pasithea Therapeutics Corp. lowest stock price was $0.65 and its highest was $7.50 in the past 12 months.
What is Pasithea Therapeutics Corp.’s market cap?
Pasithea Therapeutics Corp.’s market cap is $5.20M.
When is Pasithea Therapeutics Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pasithea Therapeutics Corp.’s earnings last quarter?
Currently, no data Available
Is Pasithea Therapeutics Corp. overvalued?
According to Wall Street analysts Pasithea Therapeutics Corp.’s price is currently Overvalued.
Does Pasithea Therapeutics Corp. pay dividends?
Pasithea Therapeutics Corp. does not currently pay dividends.
What is Pasithea Therapeutics Corp.’s EPS estimate?
Pasithea Therapeutics Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pasithea Therapeutics Corp. have?
Pasithea Therapeutics Corp. has 7,443,577 shares outstanding.
What happened to Pasithea Therapeutics Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pasithea Therapeutics Corp.?
Currently, no hedge funds are holding shares in KTTA
Company Description
Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp (KTTA) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Kazia Therapeutics
―
Theriva Biologics
―
Oragenics
―
Xenetic Biosciences
―
NLS Pharmaceutics
―
Ownership Overview
0.54% Insiders
0.05% Mutual Funds
0.77% Other Institutional Investors
95.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---